Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Ofatumumab & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

In the context of Ofatumumab & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL), ofatumumab is FDA‑approved as monotherapy for fludarabine‑ and alemtuzumab‑refractory Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL), but it is no longer authorized in the EU for CLL, including as monotherapy (1).

OS advantage not proven (2).

(1) Laurenti et al. 2016 Onco Targets Ther 9: 421-9
(2) Hilal et al. 2020 JAMA Intern. Med. 180: 1108

…

Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Hilal et al. 2020 JAMA Intern. Med. 180: 1108
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
Laurenti et al. 2016 Onco Targets Ther 9: 421-9
Review

7/1/2026